(PFE) Pfizer - Ratings and Ratios
Medicines, Vaccines, Biosimilars, Biopharmaceuticals, Therapeutics
PFE EPS (Earnings per Share)
PFE Revenue
Description: PFE Pfizer
Pfizer Inc. is a leading biopharmaceutical company that develops, manufactures, and markets a wide range of medicines and vaccines across various therapeutic areas, including cardiovascular, infectious diseases, and oncology. The companys diverse portfolio includes well-established brands such as Eliquis, Prevnar, and Ibrance, as well as newer products like Paxlovid and Comirnaty, which have gained significant traction in the market.
From a financial perspective, Pfizers market capitalization stands at approximately $147.83 billion, with a forward price-to-earnings ratio of 8.76, indicating a relatively attractive valuation compared to its peers. The companys return on equity (ROE) is around 8.78%, which is a respectable figure considering the industrys average. Additionally, Pfizers dividend yield is around 4%, making it an attractive option for income-seeking investors.
In terms of growth prospects, Pfizer has a robust pipeline, with several promising candidates in various stages of development. The companys collaboration agreements with other pharmaceutical giants, such as Bristol-Myers Squibb and BioNTech, further enhance its growth potential. Pfizers ability to generate cash from its existing products, combined with its commitment to investing in research and development, positions the company for long-term success.
Some key performance indicators (KPIs) to monitor Pfizers performance include revenue growth, particularly from its newer products; operating margin expansion, driven by cost efficiencies and pricing power; and the progress of its pipeline candidates, particularly in areas like oncology and rare diseases. Additionally, investors should keep an eye on Pfizers ability to maintain its dividend payout and return capital to shareholders through share buybacks.
PFE Stock Overview
| Market Cap in USD | 146,346m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2012-08-13 |
PFE Stock Ratings
| Growth Rating | -38.6% |
| Fundamental | 64.7% |
| Dividend Rating | 74.6% |
| Return 12m vs S&P 500 | -22.2% |
| Analyst Rating | 3.56 of 5 |
PFE Dividends
| Dividend Yield 12m | 6.85% |
| Yield on Cost 5y | 6.04% |
| Annual Growth 5y | 3.10% |
| Payout Consistency | 98.7% |
| Payout Ratio | 50.4% |
PFE Growth Ratios
| Growth Correlation 3m | 64.6% |
| Growth Correlation 12m | -61.6% |
| Growth Correlation 5y | -63% |
| CAGR 5y | -2.77% |
| CAGR/Max DD 5y | -0.05 |
| Sharpe Ratio 12m | -0.37 |
| Alpha | -16.39 |
| Beta | 0.276 |
| Volatility | 24.48% |
| Current Volume | 44228.9k |
| Average Volume 20d | 38111k |
| Stop Loss | 23.8 (-3.3%) |
| Signal | -2.13 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (10.73b TTM) > 0 and > 6% of Revenue (6% = 3.83b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 3.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.36% (prev -10.66%; Δ 20.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 15.19b > Net Income 10.73b (YES >=105%, WARN >=100%) |
| Net Debt (60.16b) to EBITDA (22.77b) ratio: 2.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (5.71b) change vs 12m ago 0.18% (target <= -2.0% for YES) |
| Gross Margin 67.34% (prev 49.11%; Δ 18.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.23% (prev 26.01%; Δ 4.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.65 (EBITDA TTM 22.77b / Interest Expense TTM 2.83b) >= 6 (WARN >= 3) |
Altman Z'' 3.54
| (A) 0.03 = (Total Current Assets 43.70b - Total Current Liabilities 37.73b) / Total Assets 206.09b |
| (B) 0.57 = Retained Earnings (Balance) 117.61b / Total Assets 206.09b |
| (C) 0.08 = EBIT TTM 15.99b / Avg Total Assets 211.14b |
| (D) 0.94 = Book Value of Equity 109.65b / Total Liabilities 117.08b |
| Total Rating: 3.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.67
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 6.41% = 3.21 |
| 3. FCF Margin 19.49% = 4.87 |
| 4. Debt/Equity 0.69 = 2.27 |
| 5. Debt/Ebitda 2.68 = -1.26 |
| 6. ROIC - WACC 9.84% = 12.31 |
| 7. RoE 11.94% = 0.99 |
| 8. Rev. Trend -50.93% = -2.55 |
| 9. Rev. CAGR -14.63% = -2.44 |
| 10. EPS Trend -29.06% = -0.73 |
| 11. EPS CAGR -32.81% = -2.50 |
What is the price of PFE shares?
Over the past week, the price has changed by -4.43%, over one month by +1.19%, over three months by +7.96% and over the past year by -8.43%.
Is Pfizer a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PFE is around 25.24 USD . This means that PFE is currently overvalued and has a potential downside of 2.6%.
Is PFE a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.8 | 17% |
| Analysts Target Price | 29.2 | 18.9% |
| ValueRay Target Price | 27.8 | 12.9% |
Last update: 2025-08-23 05:04
PFE Fundamental Data Overview
CCE Cash And Equivalents = 13.25b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 13.619
P/E Forward = 8.4388
P/S = 2.2926
P/B = 1.65
P/EG = 0.87
Beta = 0.44
Revenue TTM = 63.83b USD
EBIT TTM = 15.99b USD
EBITDA TTM = 22.77b USD
Long Term Debt = 56.63b USD (from longTermDebt, last quarter)
Short Term Debt = 4.29b USD (from shortTermDebt, last quarter)
Debt = 60.92b USD (Calculated: Short Term 4.29b + Long Term 56.63b)
Net Debt = 60.16b USD (from netDebt column, last quarter)
Enterprise Value = 194.02b USD (146.35b + Debt 60.92b - CCE 13.25b)
Interest Coverage Ratio = 5.65 (Ebit TTM 15.99b / Interest Expense TTM 2.83b)
FCF Yield = 6.41% (FCF TTM 12.44b / Enterprise Value 194.02b)
FCF Margin = 19.49% (FCF TTM 12.44b / Revenue TTM 63.83b)
Net Margin = 16.81% (Net Income TTM 10.73b / Revenue TTM 63.83b)
Gross Margin = 67.34% ((Revenue TTM 63.83b - Cost of Revenue TTM 20.85b) / Revenue TTM)
Tobins Q-Ratio = 1.77 (Enterprise Value 194.02b / Book Value Of Equity 109.65b)
Interest Expense / Debt = 1.07% (Interest Expense 654.0m / Debt 60.92b)
Taxrate = -0.35% (set to none) (from yearly Income Tax Expense: -28.0m / 8.02b)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.16 (Total Current Assets 43.70b / Total Current Liabilities 37.73b)
Debt / Equity = 0.69 (Debt 60.92b / last Quarter total Stockholder Equity 88.69b)
Debt / EBITDA = 2.68 (Net Debt 60.16b / EBITDA 22.77b)
Debt / FCF = 4.90 (Debt 60.92b / FCF TTM 12.44b)
Total Stockholder Equity = 89.88b (last 4 quarters mean)
RoA = 5.21% (Net Income 10.73b, Total Assets 206.09b )
RoE = 11.94% (Net Income TTM 10.73b / Total Stockholder Equity 89.88b)
RoCE = 10.91% (Ebit 15.99b / (Equity 89.88b + L.T.Debt 56.63b))
RoIC = 9.84% (Ebit 15.99b / (Assets 206.09b - Current Assets 43.70b))
WACC = unknown (E(146.35b)/V(207.27b) * Re(7.03%)) + (D(60.92b)/V(207.27b) * Rd(1.07%) * (1-Tc(none)))
Shares Correlation 5-Years: -60.0 | Cagr: -0.27%
Discount Rate = 7.03% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 73.62% ; FCFE base≈9.39b ; Y1≈7.15b ; Y5≈4.40b
Fair Price DCF = 14.55 (DCF Value 82.72b / Shares Outstanding 5.69b; 5y FCF grow -28.32% → 3.0% )
Revenue Correlation: -50.93 | Revenue CAGR: -14.63%
Rev Growth-of-Growth: 37.12
EPS Correlation: -29.06 | EPS CAGR: -32.81%
EPS Growth-of-Growth: 233.9
Additional Sources for PFE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle